NEW YORK (GenomeWeb News) — Nanogen this week reported it has signed a new contract with chairman and CEO Howard Birndorf for a three-year, $520,000 deal that offers potential bonuses that may be as much as 80 percent of his base salary.
The company also has signed new contracts with officers David Ludvigson, William Respess, Robert Saltmarsh, and Graham Lidgard: Ludvigson will receive a base salary of $360,000 with a $180,000 bonus potential; Lidgard will receive $290,000 with a $116,000 bonus potential; Respass will receive $329,000 with a $130,000 bonus potential; and Saltmarsh will receive $257,000 with a $103,000 bonus potential.
Per Petersen has been appointed to Invitrogen’s board of directors after retiring from his post at the chairman of R&D at Johnson & Johnson, the company said this week.
At J&J, Peterson was responsible for the Office of Science and Technology, the R&D Council, and the cell therapy research and activities. Prior to that, Peterson was chairman of the Department of Immunology at the Scripps Research Institute.
Roche has named Warwick Bedwell vice president and global head of business development of pharma partnering, the company said this week.
Bedwell was formerly general manager for Roche Philippines, and was involved in sales and marketing in Australia. He also worked with Schering-Plough in Australia and in Asia.
Gene Logic has named investment adviser Lloyd Miller to the company’s board of directors, the company said this week. Miller now “may be deemed to beneficially own” 4.5 million shares in the company, or 14.3 percent of its outstanding shares.
With the election to the board, Miller was given a grant of options to buy 30,000 shares of common stock at $1.91 a share, which would be exercisable in four installments beginning in Feb., 2008.
Hoefer Scientific Instruments has appointed Mark Daniels to be a consultant and manager for the company’s distribution network in Asia, the company said this week.
Daniels formerly supported Hoefer products in Asia with Pharmacia Biotech, Amersham Biosciences, and GE Healthcare.
Ismail Kola has been named CSO and senior vice president of discovery research at the Schering-Plough Research Institute, the company said this week. Kola replaces Catherine Strader, who now is senior vice president of science and technology.
Kola will now be responsible for a 1,000-person team of researchers in the US and in Italy, and will be a member of the company’s operations management team.
Strader will be involved in external science and technology enterprises such as business development and licensing.
RXi Pharmaceuticals, a pure-play RNAi drug company and subsidiary of CytRx, has formed a five-member board of directors.
The board includes: Todd Woolf, president and CEO of RXi; Steven Kriegsman, who was president and CEO of CytRx; Mark Ahn, president and CEO of biopharmaceutical company Hana Biosciences; Stephen Galliker, executive vice president of finance and administration and CFO of Dyax; and Sanford Hillsberg, managing partner at the law firm Troy & Gould Professional.
Xoma president and CEO Jack Castello will retire from the company, Xoma said this week.
Xoma said Castello will continue to serve in his current positions while the company seeks a successor.